1 unknown, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Attgeno AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery PDNO, Sodium chloride (placebo) - Pulmonary Hypertension | Phase 2 | Unknown | Attgeno AB | 12 | 2022-10-23 | 2023-08-01 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension Sodium chloride (placebo), PDNO - Pulmonary Hypertension, COVID-19 | Phase 1 / Phase 2 | Withdrawn | Attgeno AB | 2021-05-07 | 2023-08-01 |
Hypertension, Pulmonary (2) · COVID-19 (1)
1-(nitrosooxy)propan-2-ol and 2-(nitrosooxy)propan-1-ol drug combination (2) · Sodium Chloride (2)
Sweden (2)